Bernstein launches coverage of Canada’s Tilray, Cronos and Canopy Growth but stops short of any buy ratings

Analyst Nadine Sarwat sees Cronos and Tilray as 'fairly valued' and Canopy Growth as 'meaningfully overvalued.'